Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...

Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...

Semaglutide, the glucagon-like peptide 1 receptor agonist from Novo Nordisk A/S, which has seemingly improved every disease it’s been tested on, was a focus at Kidney Week 2024, where researchers ...

This analysis from the FLOW trial showed that once-weekly subcutaneous semaglutide 1.0 mg significantly lowered the risk of ...

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s ...

In this case report, Gad and colleagues performed corneal confocal microscopy to assess for evidence of nerve regeneration ...

It's no secret that doctors are helping many people lose weight by prescribing GLP-1 medications like Ozempic, Wegovy, ...

According to a 2023 study published in The Lancet Rheumatology, nearly 1 billion people worldwide will be affected by the most common form of arthritis: osteoarthritis. Currently, the condition ...

Although the FDA approved semaglutide for weight loss in 2021, this medication isalso used in treating type 2 diabetes and in ...

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...